RT Journal Article SR Electronic T1 Evaluation of cancer incidence among Marines and Navy personnel and civilian workers exposed to contaminated drinking water at USMC Base Camp Lejeune: a cohort study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.01.27.24301873 DO 10.1101/2024.01.27.24301873 A1 Bove, Frank J. YR 2024 UL http://medrxiv.org/content/early/2024/01/29/2024.01.27.24301873.abstract AB Background Drinking water at U.S. Marine Corps Base Camp Lejeune, North Carolina was contaminated with trichloroethylene and other industrial solvents from 1953 to 1985.Methods A cohort cancer incidence study was conducted of Marines/Navy personnel who, between 1975 and 1985, began service and were stationed at Camp Lejeune, North Carolina (N=154,821) or Camp Pendleton, California (N=163,484), and civilian workers employed at Camp Lejeune (N=6,494) or Camp Pendleton (N=5,797) between October 1972 and December 1985. Camp Pendleton’s drinking water was not known to be contaminated between 1972 and 1985. Individual-level information on all primary invasive cancers and in-situ bladder cancer diagnosed from 1996 to 2017 was obtained from data linkages with 54 cancer registries in the U.S. Survival methods were used to calculate hazard ratios (HRs) comparing cancer incidence between the Camp Lejeune and Camp Pendleton cohorts. Precision of effect estimates were evaluated using the 95% confidence interval (CI) ratio.Results Cancers among Camp Lejeune Marines/Navy personnel and civilian workers totaled 12,083 (354/100,000) and 1,563 (1,301/100,000), respectively. Cancers among Camp Pendleton Marines/Navy personnel and civilian workers totaled 12,144 (335/100,000) and 1,416 (1,372/100,000), respectively.Compared to Camp Pendleton, Camp Lejeune Marines/Navy personnel had adjusted HRs ≥1.20 with 95% CI ratios (CIRs) ≤3 for acute myeloid leukemia (HR=1.38, 95% CI: 1.03, 1.85), all myeloid cancers including polycythemia vera (HR=1.24, 95% CI:1.03, 1.49), myelodysplastic and myeloproliferative syndromes (HR=1.68, 95% CI: 1.07, 2.62), polycythemia vera alone (HR=1.41, 95% CI: 0.94, 2.11), cancers of the esophagus (HR=1.27, 95% CI: 1.03, 1.56), larynx (HR=1.21, 95% CI: 0.98, 1.50), soft tissue (HR=1.21, 95% CI: 0.92, 1.59) and thyroid (HR=1.22, 95% CI: 1.03, 1.45). Compared to Camp Pendleton, Camp Lejeune civilian workers had adjusted HRs ≥1.20 with 95% CIRs ≤3 for all myeloid cancers including polycythemia vera (HR=1.40, 95% CI: 0.83, 2.36), squamous cell lung cancer (HR=1.63, 95% CI: 1.10, 2.41) and female ductal breast cancer (HR=1.32, 95% CI:1.02, 1.71). Sensitivity analyses indicated that confounding bias due to unmeasured risk factors (e.g., smoking and alcohol consumption) is unlikely to significantly impact the findings.Conclusion Increased risks of several cancers were observed among Marines/Navy personnel and civilian workers likely exposed to contaminated drinking water at Camp Lejeune compared to personnel at Camp Pendleton.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding through interagency agreements with the U.S. Department of Health and Human Services, Agency for Toxic Substances and Disease Registry and the U.S. Department of the Navy. The author did not receive payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Centers for Disease Control and Prevention gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data referred to in the manuscript are available upon reasonable request from ATSDR Office of Science.ATSDRAgency for Toxic Substances and Disease RegistryAMLacute myeloid leukemiaBOQbachelor officer quartersCDCCenters for Disease Control and PreventionCIconfidence intervalCIRconfidence interval ratioCOPDchronic obstructive pulmonary diseaseDCEt-1,2-dichloroethyleneDMDCDefense Manpower Data CenterDODUS Department of DefenseEPAUS Environmental Protection AgencyHBHolcomb Boulevard treatment plantHPHadnot Point treatment plantHRhazard ratioIARCInternational Agency for Research on CancerICD-O-3third edition of the International Classification of Diseases for OncologyMCLEPA maximum contaminant level in drinking waterMZBCLmarginal zone B-cell lymphomaNHLnon-Hodgkin lymphomaNOSnot otherwise specifiedNTPNational Toxicology Programµg/Lmicrograms per literPCEtetrachloroethylene (also known as perchloroethylene)RRrisk ratioSEERSurveillance, Epidemiology, and End Results ProgramSIRStandardized incidence ratioSSASocial Security AdministrationSSNSocial security numberTCEtrichloroethyleneTTTarawa Terrace treatment plantUSMCUnited States Marine CorpsVAU.S. Department of Veteran AffairsWHOWorld Health Organization